- NZ$33.26m
- NZ$25.20m
- NZ$14.67m
Brief: BLIS Technologies Sees Fy19 Revenue In Excess Of NZ$7.0 Mln
Brief: BLIS Technologies Says Entered Distribution Deal With Inova Pharmaceuticals
NZ's BLIS Technologies rises to near 2-week high as Q1 losses narrow
Brief: Blis Technologies Says Fy19 Guidance For Revenue Is In Excess Of NZ$7.0 Mln
Brief: Blis Technologies Ltd Entered U.S. Market With Oral Probiotics
Brief: BLIS Technologies Says Co's Oral Probiotic BLIS M18 Obtains GRAS Status
New Zealand's BLIS Technologies hits 2-month high
Brief: Blis Technologies Posts Q3 Revenue of NZ$1.6 Million
Brief: Blis Technologies receives Streptococcus Salivarius Blis K12 approval
Brief: Blis Technologies posts HY net loss attributable of NZ$1.2 mln
Brief: Blis Technologies appoints Richard Wingham as CFO
Brief: BLIS Technologies sees trading revenue for HY18 of $2.069 mln
Brief: Blis Technologies announces resignation of CFO
Brief: Blis Technologies Ltd says Anthony Offen elected as chair
Brief: Blis Technologies receives notification that two brands have been acquired by Maspex Group
Brief: Blis Technologies expects to record a maiden profit for year to 31 March 2017
Brief: BLIS Technologies expects FY17 trading revenues in excess of NZ$8 mln
Brief: BLIS Technologies updates on outlook
Brief: BLIS Technologies affirms revenue expectations